Eli Lilly’s Foundayo Pill Cuts Heart Attack and Stroke Risk in Late-Stage Study
Eli Lilly’s Foundayo Pill Cuts Heart Attack and Stroke Risk in Late-Stage Study
Eli Lilly has reported that its newly approved oral obesity drug, Foundayo, significantly reduces the risk of major cardiovascular events in patients with type 2 diabetes and obesity, according to late-stage clinical trial results.
The study found that Foundayo lowered the risk of heart attack, stroke, or cardiovascular death by 16% compared to insulin glargine, a widely used long-acting insulin. Additionally, the drug reduced overall mortality risk by 57%, while also improving blood sugar control and supporting weight loss over a 52-week period.
Foundayo was recently approved by the U.S. Food and Drug Administration for weight loss, positioning Lilly more aggressively against rival Novo Nordisk, whose oral version of Wegovy is already on the market.
Expanding Role in Diabetes Treatment
The new data strengthens Foundayo’s potential as a dual-purpose therapy for both obesity and type 2 diabetes. Lilly plans to seek regulatory approval for the drug’s use in diabetes treatment, with an application expected by the end of the second quarter under an expedited review program.
The trial included approximately 2,700 patients at elevated cardiovascular risk, highlighting the drug’s potential to address one of the most critical complications associated with diabetes.
Competitive Push Toward Oral Therapies
The findings come amid intensifying competition in the multi-billion-dollar obesity and diabetes drug market, where pharmaceutical companies are racing to develop oral alternatives to injectable therapies.
Insulin glargine—marketed under brands such as Lantus and Basaglar—remains a standard treatment for blood sugar control. However, the convenience of oral medications like Foundayo and Wegovy is expected to reshape patient preferences and treatment strategies.
Safety Profile and Next Steps
Lilly also reported no new safety concerns related to liver function in the trial, addressing a key area of scrutiny from regulators. The FDA has previously requested additional post-marketing studies to further evaluate potential risks.
Analysts suggest the results could ease concerns about liver safety compared to competing therapies and strengthen Foundayo’s commercial outlook.
As demand for more accessible and effective metabolic treatments grows, Lilly’s latest data positions Foundayo as a strong contender in both obesity and diabetes care—particularly as the market shifts toward convenient, patient-friendly oral options.
Eli Lilly has reported that its newly approved oral obesity drug, Foundayo, significantly reduces the risk of major cardiovascular events in patients with type 2 diabetes and obesity, according to late-stage clinical trial results.
The study found that Foundayo lowered the risk of heart attack, stroke, or cardiovascular death by 16% compared to insulin glargine, a widely used long-acting insulin. Additionally, the drug reduced overall mortality risk by 57%, while also improving blood sugar control and supporting weight loss over a 52-week period.
Foundayo was recently approved by the U.S. Food and Drug Administration for weight loss, positioning Lilly more aggressively against rival Novo Nordisk, whose oral version of Wegovy is already on the market.
Expanding Role in Diabetes Treatment
The new data strengthens Foundayo’s potential as a dual-purpose therapy for both obesity and type 2 diabetes. Lilly plans to seek regulatory approval for the drug’s use in diabetes treatment, with an application expected by the end of the second quarter under an expedited review program.
The trial included approximately 2,700 patients at elevated cardiovascular risk, highlighting the drug’s potential to address one of the most critical complications associated with diabetes.
Competitive Push Toward Oral Therapies
The findings come amid intensifying competition in the multi-billion-dollar obesity and diabetes drug market, where pharmaceutical companies are racing to develop oral alternatives to injectable therapies.
Insulin glargine—marketed under brands such as Lantus and Basaglar—remains a standard treatment for blood sugar control. However, the convenience of oral medications like Foundayo and Wegovy is expected to reshape patient preferences and treatment strategies.
Safety Profile and Next Steps
Lilly also reported no new safety concerns related to liver function in the trial, addressing a key area of scrutiny from regulators. The FDA has previously requested additional post-marketing studies to further evaluate potential risks.
Analysts suggest the results could ease concerns about liver safety compared to competing therapies and strengthen Foundayo’s commercial outlook.
As demand for more accessible and effective metabolic treatments grows, Lilly’s latest data positions Foundayo as a strong contender in both obesity and diabetes care—particularly as the market shifts toward convenient, patient-friendly oral options.
